Peptidomimetic inhibitor of L-plastin reduces osteoclastic bone resorption in aging female mice

Abstract

L-plastin (LPL) was identified as a potential regulator of the actin-bundling process involved in forming nascent sealing zones (NSZs), which are precursor zones for mature sealing zones. TAT-fused cell-penetrating small molecular weight LPL peptide (TAT- MARGSVSDEE, denoted as an inhibitory LPL peptide) attenuated the formation of NSZs and impaired bone resorption in vitro in osteoclasts. Also, the genetic deletion of LPL in mice demonstrated decreased eroded perimeters and increased trabecular bone density. In the present study, we hypothesized that targeting LPL with the inhibitory LPL peptide in vivo could reduce osteoclast function and increase bone density in a mice model of low bone mass. We injected aging C57BL/6 female mice (36 weeks old) subcutaneously with the inhibitory and scrambled peptides of LPL for 14 weeks. Micro-CT and histomorphometry analyses demonstrated an increase in trabecular bone density of femoral and tibial bones with no change in cortical thickness in mice injected with the inhibitory LPL peptide. A reduction in the serum levels of CTX-1 peptide suggests that the increase in bone density is associated with a decrease in osteoclast function. No changes in bone formation rate and mineral apposition rate, and the serum levels of P1NP indicate that the inhibitory LPL peptide does not affect osteoblast function. Our study shows that the inhibitory LPL peptide can block osteoclast function without impairing the function of osteoblasts. LPL peptide could be developed as a prospective therapeutic agent to treat osteoporosis.

References

[1] Demontiero O, Vidal C, Duque G. Aging and bone loss: new insights for the clinician. Ther. Adv. Musculoskelet. Dis., 2012, 4:61-76

[2] Lecka-Czernik B. PPARs and bone metabolism. PPAR Res., 2006, 2006:18089

[3] Kajkenova O et al. Increased adipogenesis and myelopoiesis in the bone marrow of SAMP6, a murine model of defective osteoblastogenesis and low turnover osteopenia. J. Bone Miner. Res., 1997, 12:1772-1179

[4] Lazarenko OP et al. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology, 2007, 148:2669-2680

[5] Delanote V, Vandekerckhove J, Gettemans J. Plastins: versatile modulators of actin organization in (patho)physiological cellular processes. Acta Pharmacol. Sin., 2005, 26:769-779

[6] Namba Y, Ito M, Zu Y, Shigesada K, Maruyama K. Human T cell L-plastin bundles actin filaments in a calcium-dependent manner. J. Biochem., 1992, 112:503-507

[7] Janji B et al. Phosphorylation on Ser5 increases the F-actin-binding activity of L-plastin and promotes its targeting to sites of actin assembly in cells. J. Cell Sci., 2006, 119:1947-1960

[8] Lin CS, Lau A, Lue TF. Analysis and mapping of plastin phosphorylation. DNA Cell Biol., 1998, 17:1041-1046

[9] Si M et al. LRRK1 regulation of actin assembly in osteoclasts involves serine 5 phosphorylation of L-plastin. J. Cell Biochem., 2018, 119:10351-10357

[10] Ma T, Sadashivaiah K, Chellaiah MA. Regulation of sealing ring formation by L-plastin and cortactin in osteoclasts. J. Biol. Chem., 2010, 285:29911-29924

[11] Chellaiah MA, Ma T, Majumdar S. L-plastin phosphorylation regulates the early phase of sealing ring formation by actin-bundling process in mouse osteoclasts. Exp. Cell Res., 2018, 372:73-82

[12] Majumdar S et al. Engineering of L-plastin peptide-loaded biodegradable nanoparticles for sustained delivery and suppression of osteoclast function in vitro. Int. J. Cell Biol., 2019, 2019:6943986

[13] Chellaiah MA, Majumdar S, Aljohani H. Peptidomimetic inhibitors of L-plastin reduce the resorptive activity of osteoclast but not the bone-forming activity of osteoblasts in vitro. PLoS. ONE., 2018, 13

[14] Chellaiah MA et al. L-Plastin deficiency produces increased trabecular bone due to attenuation of sealing ring formation and osteoclast dysfunction. Bone Res., 2020, 8:3

[15] Jilka RL. The relevance of mouse models for investigating age-related bone loss in humans. J. Gerontol. A Biol. Sci. Med. Sci., 2013, 68:1209-1217

[16] Glatt V, Canalis E, Stadmeyer L, Bouxsein ML. Age-related changes in trabecular architecture differ in female and male C57BL/6J mice. J. Bone Miner. Res., 2007, 22:1197-1207

[17] Halloran BP et al. Changes in bone structure and mass with advancing age in the male C57BL/6J mouse. J. Bone Miner. Res., 2002, 17:1044-1050

[18] Gimble JM, Nuttall ME. The relationship between adipose tissue and bone metabolism. Clin. Biochem., 2012, 45:874-879

[19] Garanty-Bogacka B et al. Association between serum osteocalcin, adiposity and metabolic risk in obese children and adolescents. Endokrynol. Pol., 2013, 64:346-352

[20] Ferguson VL, Ayers RA, Bateman TA, Simske SJ. Bone development and age-related bone loss in male C57BL/6J mice. Bone, 2003, 33:387

[21] Willinghamm MD et al. Age-related changes in bone structure and strength in female and male BALB/c mice. Calcif. Tissue Int., 2010, 86:470-483

[22] Khosla S. Estrogen and bone: insights from estrogen-resistant, aromatase-deficient, and normal men. Bone, 2008, 43:414-417

[23] Khosla S et al. Effects of sex and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo assessment. J. Bone Miner. Res., 2006, 21:124-131

[24] Riggs BL et al. A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. J. Bone Miner. Res., 2008, 23:205-214

[25] Eastell R et al. Postmenopausal osteoporosis. Nat. Rev. Dis. Primers, 2016, 2:16069

[26] Ebeling PR. Clinical practice. Osteoporosis in men. N. Engl. J. Med., 2008, 358:1474-1482

[27] Almeida M et al. Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J. Biol. Chem., 2007, 282:27285-27297

[28] Parfitt AM. Age-related structural changes in trabecular and cortical bone: cellular mechanisms and biomechanical consequences. Calcif. Tissue Int., 1984, 36:S123-S128

[29] Freeley M et al. L-plastin regulates polarization and migration in chemokine-stimulated human T lymphocytes. J. Immunol., 2012, 188:6357-6370

[30] Jimenez L et al. miR-375 regulates invasion-related proteins vimentin and L-plastin. Am. J. Pathol., 2017, 187:1523-1536

[31] Morley SC. The actin-bundling protein L-plastin: a critical regulator of immune cell function. Int. J. Cell Biol., 2012, 2012:935173

[32] Park T, Chen ZP, Leavitt J. Activation of the leukocyte plastin gene occurs in most human cancer cells. Cancer Res., 1994, 54:1775-1781

[33] Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone., 2011, 48:677-692

[34] Dai R et al. Cathepsin K: the action in and beyond bone. Front. Cell Dev. Biol., 2020, 8:433

[35] Drake MT, Clarke BL, Oursler MJ, Khosla S. Cathepsin K inhibitors for osteoporosis: biology, potential clinical utility, and lessons learned. Endocr. Rev., 2017, 38:325-350

[36] Scotland G et al. Denosumab for the prevention of osteoporotic fractures in postmenopausal women: a NICE single technology appraisal. Pharmacoeconomics., 2011, 29:951-961

[37] Teitelbaum, S. L. Therapeutic implications of suppressing osteoclast formation versus function. Rheumatology (Oxford) 55, ii61–ii63 (2016).

[38] Nieves JW, Cosman F. Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates. Curr. Osteoporos. Rep., 2010, 8:34-39

[39] Sellmeyer DE. Atypical fractures as a potential complication of long-term bisphosphonate therapy. JAMA, 2010, 304:1480-1484

[40] Takahashi M et al. Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review. BMC Cancer, 2019, 19

[41] Chavassieux P et al. Bone-forming and antiresorptive effects of romosozumab in postmenopausal women with qsteoporosis: bone histomorphometry and microcomputed tomography analysis after 2 and 12 months of treatment. J. Bone Miner. Res., 2019, 34:1597-1608

[42] Ishibashi H et al. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: a phase 2 study. Bone, 2017, 103:209-215

[43] Slaton RM, Boyd K, Iranikhah M. Romosozumab and sequential therapy in postmenopausal osteoporosis. Sr Care Pharm., 2020, 35:297-308

[44] Bovijn, J. et al. Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics. Sci. Transl. Med. 12, eaay6570 (2020).

[45] Brown JP et al. Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet, 1984, 1:1091-1093

[46] Delmas PD, Christiansen C, Mann KG, Price PA. Bone Gla protein (osteocalcin) assay standardization report. J. Bone Miner. Res., 1990, 5:5-11

[47] Delmas PD et al. Serum bone gamma carboxy glutamic acid-containing protein in primary hyperparathyroidism and malignant hypercalcemia. Comparison with bone histomorphometry. J. Clin. Investig., 1986, 77:985-991

[48] Rossi M, Battafarano G, Pepe J, Minisola S, Del Fattore A. The endocrine function of osteocalcin regulated by bone resorption: a lesson from reduced and increased bone mass diseases. Int. J. Mol. Sci., 2019, 20:4502

[49] Kanazawa I et al. Serum osteocalcin level is positively associated with insulin sensitivity and secretion in patients with type 2 diabetes. Bone, 2011, 48:720-725

[50] Zoch ML, Clemens TL, Riddle RC. New insights into the biology of osteocalcin. Bone, 2016, 82:42-49

[51] Lerner UH. Bone remodeling in postmenopausal osteoporosis. J. Dent. Res., 2006, 85:584-595

[52] Nicks KM et al. Deletion of estrogen receptor beta in osteoprogenitor cells increases trabecular but not cortical bone mass in female mice. J. Bone Miner. Res., 2016, 31:606-614

[53] Pierce JL, Begun DL, Westendorf JJ, McGee-Lawrence ME. Defining osteoblast and adipocyte lineages in the bone marrow. Bone, 2019, 118:2-7

[54] Keune JA, Wong CP, Branscum AJ, Iwaniec UT, Turner RT. Bone marrow adipose tissue deficiency increases disuse-induced bone loss in male mice. Sci. Rep., 2017, 7

[55] Shapiro, I. & Haselgrove, J. In Energy metabolism in bone (ed Hall, B.) Bone, 99–140 (CRC Press, 1991).

[56] Zhang Q, Riddle RC, Clemens TL. Bone and the regulation of global energy balance. J. Intern. Med., 2015, 277:681-689

[57] Nguyen J et al. Synthetic peptide CK2.3 enhances bone mineral density in senile mice. J. Bone Res., 2018, 6:190

[58] Pountos I et al. The role of peptides in bone healing and regeneration: a systematic review. BMC Med., 2016, 14

[59] Mercado AE, Yang X, He X, Jabbari E. Effect of grafting BMP2-derived peptide to nanoparticles on the osteogenic and vasculogenic expression of stromal cells. J. Tissue Eng. Regen. Med., 2014, 8:15-28

[60] Park SH et al. Branched oligomerization of cell-permeable peptides markedly enhances the transduction efficiency of adenovirus into mesenchymal stem cells. Gene Ther., 2010, 17:1052-1061

[61] Suh JS et al. Intracellular delivery of cell-penetrating peptide-transcriptional factor fusion protein and its role in selective osteogenesis. Int. J. Nanomedicine, 2014, 9:1153-1166

[62] Dai S, Hirayama T, Abbas S, Abu-Amer Y. The IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J. Biol. Chem., 2004, 279:37219-37222

[63] Gupta A et al. Leupaxin is a critical adaptor protein in the adhesion zone of the osteoclast. J. Bone Miner. Res., 2003, 18:669-685

[64] Chellaiah M et al. Gelsolin deficiency blocks podosome assembly and produces increased bone mass and strength. J. Cell Biol., 2000, 148:665-678

[65] Chellaiah M et al. Rho-A is critical for osteoclast podosome organization, motility, and bone resorption. J. Biol. Chem., 2000, 275:11993-12002

[66] Buo AM, Tomlinson RE, Eidelman ER, Chason M, Stains JP. Connexin43 and Runx2 interact to affect cortical bone geometry, skeletal development, and osteoblast and osteoclast function. J. Bone Miner. Res., 2017, 32:1727-1738

[67] Moorer MC et al. Defective signaling, osteoblastogenesis and bone remodeling in a mouse model of connexin 43 C-terminal truncation. J. Cell Sci., 2017, 130:531-540

[68] Dempster DW et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res., 2013, 28:2-17

[69] Chellaiah MA et al. Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression. Mol. Biol. Cell, 2003, 14:173-189

[70] Jilka RL, Weinstein RS, Takahashi K, Parfitt AM, Manolagas SC. Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence. J. Clin. Investig., 1996, 97:1732-1740

[71] Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. The effects of androgen deficiency on murine bone remodeling and bone mineral density are mediated via cells of the osteoblastic lineage. Endocrinology, 1997, 138:4013-4021

[72] Parfitt AM et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. J. Bone Miner. Res., 1987, 2:595-610

[73] Li X et al. Stimulation of Piezo1 by mechanical signals promotes bone anabolism. Elife, 2019, 8:e49631

[74] Jepsen KJ, Silva MJ, Vashishth D, Guo XE, van der Meulen MC. Establishing biomechanical mechanisms in mouse models: practical guidelines for systematically evaluating phenotypic changes in the diaphyses of long bones. J. Bone Miner. Res., 2015, 30:951-966